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Purpose: To determine the national surgical practice patterns of
care for operable lung cancer patients treated with radiation.
Materials and Methods: A nationwide survey of a stratified ran-
dom sample of institutions was conducted for patients who had
non-metastatic lung cancer, Karnofsky Performance Scores (KPS)
60, and who had received radiation therapy as definitive or
adjuvant treatment. Among 541 patients, representing a weighted
sample size of 42,335 patients nationwide, 131 (19.8%) underwent
surgery as part of their therapy. Pearson 2 statistics were used to
analyze characteristics of this subset of patients.
Results: Of the 131 patients who underwent surgery, 126 patients
who had non-small cell lung cancer (NSCLC) were analyzed.
Surgical patients were younger, had less weight loss, higher KPS,
and higher forced expiratory volume within 1 second (FEV1) values
than those treated without surgery. Surgical patients had more stage
I/II (53.5% vs 32.2%; p  0.0004) and less clinical N2/N3 disease
(28.8% vs 47.5%; p  0.002) than nonsurgical patients. Surgery
consisted of lobectomy or bilobectomy in 63.2% of patients, pneu-
monectomy in 23.5%, and wedge resection in 5.9%. Of the patients,
80.4% received radiation in the adjuvant setting and 9.9% in the
neoadjuvant setting.
Conclusions: Patients with non-metastatic lung cancer who are
treated surgically and with radiation have clinically less advanced
disease than those treated with radiation alone. Most radiation
therapy in this setting is administrated postoperatively and second-
ary to hilar and/or mediastinal nodal involvement undetected before
surgery. Improved preoperative nodal staging and neoadjuvant ap-
proaches may alter these practice patterns.
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The Patterns-of-Care Study (PCS) has emerged as a uniquemethod of assessing national practice patterns associated
with a variety of cancers. Reports on the use of radiation in
the treatment of prostate, breast, and colon cancers have
revealed the correspondence between recommended and ac-
tual treatment.1–3 Given the enormous impact of lung cancer
on the population, the PCS model was recently applied to it.
Lung cancer remains the number one cause of cancer
death in the United States. It is estimated that it will cause
162,460 deaths in 2006,4 more than the number of deaths
from breast, prostate, and colorectal cancers combined. Non-
small cell lung cancer (NSCLC) accounts for approximately
80% to 85% of lung cancer cases, and small cell lung cancer
(SCLC) accounts for the remainder. Despite increased re-
search and improvements in combined modality treatments,
the prognosis for lung cancer patients remains dismal. The
overall 5-year survival rate for 1995 to 2001 was only
15.3%.5
In 2003, the results of the first PCS involving radiation
therapy for lung cancer were published.6 Later, the same data
set was analyzed to specifically examine the use of chemo-
therapy.7 These analyses summarized practice patterns in
patients treated with radiation for NSCLC and SCLC in 1998
and 1999 in a wide array of care facilities. One goal of these
studies was to determine whether results of positive clinical
trials were being incorporated into routine practice. At the
time, reports of randomized clinical trials8 and meta-analy-
ses9 supported the use of combined chemotherapy and radi-
ation compared with radiation alone. The results of the PCS
analyses6,7 showed that combined modality treatment had
been adopted and was typically used in the care of limited
stage SCLC and locally advanced NSCLC. It was concluded
that current practice in the United States generally matched
evidence-based literature recommendations for locally ad-
vanced disease.
We revisited the PCS data set6,7 to analyze the use of
surgery among patients treated with radiation therapy. Spe-
cifically, we analyzed the type of surgery, nodal staging,
completeness of resection, and timing of radiation with re-
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spect to surgery. We also reviewed the effects of race, age,
gender, co-morbidities, and other non-clinical factors on
patients who received surgery.
PATIENTS AND METHODS
Patient Population:
To select representative patients of the total population,
we used a stratified two-stage sampling design to choose
centers and patients for data collection. A comprehensive list
of radiation therapy facilities in the United States were
stratified into three groups: academic centers (including the
main teaching hospitals of medical schools or National Can-
cer Institute comprehensive cancer center designees), large
non-academic facilities (including centers that treat 500 or
more new radiation therapy patients per year), and small
non-academic facilities (including those treating fewer than
500 new radiation-therapy patients per year). The sample was
then drawn independently from each group (stratum). Eighty
facilities were randomly selected from the three strata and
invited to participate in the survey, although two of those
facilities closed before the survey began. Data were collected
at on-site chart reviews in 2000 to 2002 by PCS research
employees at 22 academic centers, 19 large nonacademic
centers, and 18 small non-academic centers, for a participa-
tion rate of 76%. In the second stage of sampling, cases of
lung cancer were randomly selected for further data review
and abstraction based on lists provided by each selected
facility according to standard eligibility criteria.
To be eligible for retrospective review in this study,
each patient had to meet several criteria: treatment adminis-
tered during 1998 and 1999, AJCC 1997 nonmetastatic lung
cancer (stages I-III), use of radiation for definitive or adjuvant
treatment, and a Karnofsky performance score (KPS) of at
least 60. On the basis of those criteria, a weighted sample size
(wss) of 42,355 patients was gleaned, and 541 patient records
were individually reviewed by PCS-trained researchers. The
detailed analysis included information regarding patient de-
mographics, staging, and treatment. Of the 541 patients, 131
representing 8398 (wss) underwent surgery as part of their
therapy. Among 131 surgical patients, 126 (representing
8214) had NSCLC.
Statistical Analysis
National estimates were calculated from the survey data
using SUDAAN statistical software (Research Triangle Insti-
tute, Research Triangle Park, NC), which incorporates the
design elements (two stages of stratification) and weights that
reflect the relative contribution of each institution and each
patient in the analysis of this complex survey. The weights
were the product of the following two factors:
All figures calculated using SUDAAN were national
estimates for the patient population defined by the eligibility
criteria. Tests for association were performed using the Pear-
son 2 statistic in SUDAAN. Differences were deemed sig-
nificant if the associated p values were 0.05. Details of
surgical resection, nodal staging, completeness of resection,
and timing of radiation therapy and chemotherapy with re-
spect to surgery were specifically investigated.
RESULTS
The patient and tumor characteristics of the entire study
population were analyzed. The median age at the time of
radiation therapy was 67 years (range, 29 to 92 years). The
population was 61% male and 39% female. Only 3.9% of the
patients were never-smokers, and 38% were active smokers
at the time of treatment. Approximately 83% of the patients
had KPS of 80 or greater, and 61% had a co-morbidity
identified in their medical histories. Approximately 85.5% of
patients had a diagnosis of NSCLC, and 14.5% had a diag-
nosis of SCLC, as estimated from wss. Those proportions are
consistent with expected distribution from SEER database
studies.5 The clinical stage distribution was 15.4%, 18.5%,
58.3%, and 7.8% for stage I, stage II, stage III, and unknown,
respectively.
With regard to staging, 97.8% of all patients had chest
computed tomographic (CT) scans, 56.1% had bone scans,
and 2.6% had positron-emission tomographic (PET) scans.
For evaluation of brain metastases, 38.8% had brain CT
scans, and 11.0% had brain magnetic resonance imaging
(MRI). Of the NSCLC surgical patients, 50.9% had patho-
logic staging of the mediastinum; among them, 20.6% had a
transbronchial nodal biopsy for staging, 56.5% had medias-
tinoscopy, 16.3% had anterior mediastinotomy, and a 1.1%
had a video-assisted thoracic procedure.
Overall, 19.8% of the study population underwent sur-
gery. Of the surgical patients, 97.8% had NSCLC compared
with 85.5% of the overall population. These patients with
NSCLC are the focus of the remainder of the analysis, and the
relationship between specific patient characteristics and
the use of surgery in NSCLC is shown in Table 1. Of these,
the patients treated who underwent surgery were younger
than those who did not (mean age, 60.6 versus 68.9 years;
p  0.0001). They also tended to have higher performance
status: 93.4% had KPS of 80 or greater versus 79% of
nonsurgical patients (p  0.001). Surgical patients also had
higher FEV1 measurements; 20.3% of surgical patients had
FEV1 greater than 2 L versus 3.3% of nonsurgical patients
(p  0.03). Finally, fewer surgical patients than nonsurgical
patients had pretreatment weight loss of more than 5% (14%
versus 26%; p  0.06). There were no statistical differences
in previously identified co-morbidities, race, or gender be-
tween the surgical and nonsurgical groups.
The relationship between disease characteristics and
use of surgery in NSCLC is shown in Table 2. There was no
statistically significant difference between surgical and non-
surgical patients in clinical T stages. However, surgical pa-
tients had more clinical stage I/II (53.5% versus 32.2%; p 
0.0004) and less clinical N2/N3 disease (28.8% versus
47.5%; p  0.002) than nonsurgical patients. The final
pathological stage in surgical patients is listed in Table 2. The
details of the surgical procedures are listed in Table 3.
Surgery consisted of lobectomy or bilobectomy in 63.2% of
patients, pneumonectomy in 23.5%, wedge resection in 5.9%,
exploration alone (no resection) for 11.1%, and unknown
surgery type for 1.1%. For patients who underwent surgery,
pathological staging was 9.5% stage I, 35.9% stage II, 45.1%
stage III, and 9.5% unknown, according to AJCC 1997
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staging system. Of patients who received surgery, 28% had
pathological N2 and 2% had N3 disease. Of the surgically
resected tumors, 55.8% were considered R0 (all margins
pathologically negative), 17.0% were considered R1 (micro-
scopically positive margins or residual microscopic disease),
and 2.0% were considered R2 (gross residual disease or
macroscopically positive margins); 25.2% were unknown.
The mean number of lymph nodes sampled during resection
was 7.8 (range, 0 to 73), and the mean number of lymph
nodes positive was 1.57 (range, 0 to 16). Extracapsular nodal
extension was noted in specimens from 3.2% of patients.
By definition, all patients in this study had received
radiation therapy. Of those who had radiation and surgical
resection, 80.4% underwent surgery before radiation, 9.9%
after radiation, 9.7% unknown. Of those who had radiation
and surgical resection, 46.2% also had chemotherapy: 10.8%
preoperatively, 68.3% postoperatively, and 7.7% preopera-
tively and postoperatively (13.2% unknown). There was no
difference in the percentage of patients who received chemo-
therapy between surgical and non-surgical patients.
The use of surgery was not statistically related to the
type of institution at which the patient received radiation
treatment: 29.7% of patients at academic institutions, 21.1%
at large non-academic institutions, and 17.5% at smaller
non-academic institutions underwent surgery.
In a logistic regression analysis, several factors were
associated with an increased likelihood of surgery in NSCLC:
age 70 years (OR, 5.5; p  0.0002), FEV1 2 L (OR, 6.4;
p  0.02), and N1 disease (OR, 6.7; p  0.008). Race, gender,
type of institution, and KPS did not predict surgical intervention.
TABLE 1. Pretreatment patient characteristics and use of surgery
Received surgery Did not receive surgery
Characteristic
Weighted sample size
(unweighted) Percentagea
Weighted sample size
(unweighted) Percentagea
Total 8,214 (126) 22.7 27,983 (343) 77.3
Age (yr)b (p  0.0004)
70 6,443 (91) 78.4 13,504 (180) 48.3
70 1,771 (35) 21.6 14,446 (162) 51.7
Sex (p  0.9870)
Male 5,150 (74) 62.7 17,517 (204) 62.6
Female 3,064 (52) 37.3 10,466 (139) 37.4
Race (p  0.6184)
Caucasian 6,639 (107) 80.8 22,418 (256) 80.1
Black / African-American 1,264 (13) 15.4 4,878 (70) 17.4
Hispanic / Latino 89 (4) 1.1 271 (7) 1.0
Asian 222 (2) 2.7 65 (5) 0.2
Other 0 0 351 (5) 1.3
KPS (p  0.0186)
60 0 0 1,171 (15) 4.2
70 541 (7) 6.6 4,672 (51) 16.7
80 3,102 (46) 37.8 12,103 (164) 43.3
90 3,980 (67) 48.5 9,297 (103) 33.2
100 590 (6) 7.2 709 (9) 2.5
Unknown 0 0 31 (1) 0.1
Co-morbidity (p  0.8105)
Yes 4,668 (62) 56.8 17,004 (214) 60.8
No 3,312 (62) 40.3 10,351 (121) 37.0
Unknown 234 (2) 2.9 629 (8) 2.2
Weight loss 5% (p  0.0940)
Yes 1,150 (19) 14.0 7,293 (95) 26.1
No 4,107 (78) 50.0 11,396 (147) 40.7
Unknown 2,957 (29) 36.0 9,295 (101) 33.2
FEV1.0 (p  0.0341)
1 L 61 (1) 0.7 2,744 (33) 9.8
1-2 L 1,999 (25) 24.3 3,957 (50) 14.1
2 L 1,669 (24) 20.3 926 (15) 3.3
Unknown 4,484 (76) 54.6 20,355 (245) 72.7
a Based on the weighted number of patients. b Excludes one patient with unknown age.
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DISCUSSION
This PCS analysis was designed to assess the use of
radiation therapy in lung cancer patients, but the results also
offer insight into the use of surgery in clinical practice for
patients with operable lung cancer treated with radiotherapy.
Overall, the patient populations and distribution of histolog-
ical characteristics are consistent with expected national sta-
tistics.4 Specifically, the breakdown between NSCLC
(85.5%) and SCLC (14.5%) has been previously documented.
As expected, the use of surgery was significantly asso-
ciated with histological characteristics and initial staging.
Overall, 19.8% of patients received surgery in addition to
radiation as part of their care. Surgery was used much more
often in NSCLC patients, which is consistent with SCLC
being considered a systemic disease. The relatively low
proportion of surgical patients in this PCS probably reflects
selection bias. Patients with early stage, surgically curable
disease are unlikely to have also received radiation therapy.
Similarly, patients with advanced mediastinal disease (N3) or
large T4 lesions would have been ineligible for surgery.
Indeed, most of the surgical patients assessed in this study
had stage I or II disease; a smaller number had stage III
disease. Only 2.5% of patients with pathological N3 disease
underwent surgical resection; this is consistent with the Na-
tional Comprehensive Cancer Network (NCCN) recommen-
dation that patients with bilateral mediastinal disease receive
chemotherapy and radiation as definitive treatment.12
Some patients who had extensive disease were treated
with surgery. That probably reflects incomplete preoperative
staging workups. In fact, only 2.6% of patients had PET
scans, 56.1% had bone scans, and 47.1% had brain scans (CT,
MRI, or both) during their evaluation process. This pattern of
care will probably change as preoperative workups become
more extensive with increased use of PET scanning (which
was often not available at the time these patients were
diagnosed) and patients are better staged at the initiation of
treatment. Most likely, that will upstage the proportion of
patients and reduce the use of upfront surgery in this popu-
lation.
As we anticipated, patients treated with radiation and
surgery were younger, had less weight loss, higher KPS, and
higher FEV1 value compared with patients treated with
radiotherapy alone,. Surgical patients also had more stage I/II
(53.5% versus 32.2%; p  0.0004) and less clinical N2/N3
disease (28.8% versus 47.5%; p  0.002) than non-surgical
patients. However, there was no significant difference in T
stage between surgical and non-surgical patients (p  0.26).
In general, T4 disease is considered to be inoperable except
for satellite lesions in the same lobe. In the current study,
8.4% patients in the surgical group had T4 disease, compared
with 14.8% in the non-surgical group. In some institutions,
patients with limited involvement of vertebral body, atria
were operated, and postoperative radiotherapy usually fol-
lowed. Because all of our patients received radiotherapy as
TABLE 2. Disease characteristics and use of surgery
Received surgery Did not receive surgery
Clinical stage Pathological stage Clinical stage
Characteristic
Weighted sample size
(unweighted) Percentagea
Weighted sample size
(unweighted) Percentagea
Weighted sample size
(unweighted) Percentagea
Total 8,214 (126) 22.7 8,214 (216) 22.7 27,983 (343) 77.3
Stage
I 1,312 (15) 16.0 777 (9) 9.5 4,726 (55) 16.9
II 3,083 (39) 37.5 2,952 (41) 35.9 4,284 (47) 15.3
III 3,752 (63) 45.7 3,704 (61) 45.1 17,945 (232) 64.1
Unknown 66 (9) 0.8 780 (15) 9.5 1,027 (9) 3.7
T stage (primary)
TX 77 (2) 0.9 109 (4) 1.3 505 (7) 1.8
T1 1,530 (20) 18.6 2,240 (23) 27.3 4,222 (47) 15.1
T2 3,391 (45) 41.3 2,156 (41) 26.3 11,152 (132) 39.9
T3 2,116 (31) 25.8 1,912 (30) 23.3 5,564 (63) 19.9
T4 694 (11) 8.4 800 (11) 9.7 4,152 (54) 14.8
Unknown 407 (17) 4.9 997 (17) 12.1 2,388 (40) 8.5
N stage (regional lymph nodes)
NX 559 (9) 6.8 284 (6) 3.5 4,162 (48) 14.9
N0 2,608 (32) 31.8 1,822 (25) 22.2 6,108 (64) 21.8
N1 2,275 (27) 27.7 2,694 (35) 32.3 2,084 (30) 7.4
N2 2,321 (40) 28.3 2,304 (39) 28.0 11,549 (128) 41.3
N3 45 (1) 0.5 165 (5) 2.0 1,741 (32) 6.2
Unknown 407 (17) 4.9 991 (16) 12.1 2,339 (41) 8.4
a Based on the weighted number of patients.
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part of their treatment, it is quite possible that more advanced
T and N stage patients were collected in the current study
compared with patients who received surgery alone.
A PCS that analyzed the treatment of NSCLC with all
modalities in 199610 surveyed a population-based random
sample of 898 patients. Only 52% of the patients received the
recommended therapy, and race, age, and marital status had
profound implications for the correspondence between actual
and recommended treatment as defined by the American
Society for Clinical Oncology, the National Cancer Institute,
and the American College of Chest Surgeons.11,12 Older,
Caucasian, married patients were more likely to receive the
recommended therapy. Of the 240 patients with stage I or II
disease, 69% underwent lobectomy or pneumonectomy, 10%
underwent more limited surgical resection, 16% received
radiation alone, and 5% received no therapy. Of those who
underwent surgery, 80% received it as definitive therapy
alone and 20% as part of combined-modality treatment with
chemotherapy, radiation, or both. Patients who underwent the
recommended surgery were younger than those who did not.
Although the differences did not reach statistical significance,
patients who underwent the recommended surgery were also
more likely to be non-Hispanic Whites, currently married,
without recorded co-morbidity, and current or former smok-
ers.10 The authors contended that the disparities in care—which
corresponded to such non-clinical factors as age, race, co-
morbidities, and type of hospital—have been previously recog-
nized13–16 and may reflect underlying controversies in recom-
mended therapy, access to care, and patient preferences.
In contrast with a previous report,10 differences in the
frequency of surgery did not seem to be related to gender or
race in our study. In addition, the likelihood of surgery was
not associated with the type or size of facility at which a
patient was treated. However, age was a major factor in
surgical intervention, despite similarities in co-morbidity be-
tween the surgical and nonsurgical groups. That finding may
lead to the conclusion that surgery is less likely to be
performed on patients older than 70 years regardless of their
overall health. Elderly patients without co-morbidities may
be adversely affected by this disparity. As the American
population ages, a greater proportion of patients will be older
than 70 years; if their co-morbidities are not substantially
different from that of their younger counterparts, withholding
surgery may be difficult to justify.
There are important limitations of this PCS analysis
with regard to patterns of surgery in the United States.
Specifically, our sampling of patients is limited by the orig-
inal aim of the study; only radiotherapy facilities were sur-
veyed, and the patients studied were selected according to the
use of radiation in their treatment. As a result, the analysis
misses a large segment of surgical patients who received
definitive treatment without radiation, thereby removing a
substantial population of stage I patients from our analysis. In
addition, it may be biased toward patients upstaged during
surgery, in that such patients are more likely to receive
radiation therapy. Indeed, the high proportion of R1 and R2
resections in this population likely reflects this underlying
bias. Regardless, radiation and surgery are both key compo-
nents of multimodality treatment of lung cancer and often are
used together.
The role of postoperative radiotherapy in NSCLC re-
mains controversial. The Lung Cancer Study Group (LCSG)
conducted a randomized trial to evaluate the role of postop-
erative radiotherapy alone in patients with completely re-
sected stages II and III epidermoid (squamous cell) NSCLC.
The result showed no difference in survival between patients
with and without postoperative radiotherapy.17 However, the
patients who received radiotherapy had a significant decrease
in local recurrence (1% versus 19% of all patients; p 0.05).
In addition, patients with N2 disease seemed to have a
disease-free survival benefit from postoperative radiotherapy.
The Postoperative Radiation Therapy (PORT) meta-analysis
study in 1998 reported that postoperative radiotherapy was
detrimental to survival because of increased non-cancer–
related mortality.18 A recent analysis conducted at Memorial
Sloan-Kettering Cancer Center showed that this PORT meta-
analysis seems to be changing practice patterns, decreasing
the application of postoperative radiotherapy. This PORT
analysis, however, has been the subject of substantial criti-
cism. First, it included many patients with stage I and II
disease for whom there was no clear indication to have
postoperative radiotherapy in the first place. Indeed, subgroup
analysis in this PORT study showed that the reduced survival
only applied to stage I and II, not stage III, disease. Second,
many patients in this analysis were treated with poor radiation
techniques, including the use of large treatment volumes
without CT plan and Cobalt-based irradiation. According to
TABLE 3. Characteristics of surgery
Received surgery
Characteristic
Weighted sample size
(unweighted) Percentagea
Total 8,214 (126) 22.7
Type of surgeryb
Exploration alone (no resection) 910 (17) 11.1
Wedge 481 (13) 5.9
Lobectomy 4,959 (70) 60.4
Bilobectomy 227 (7) 2.8
Pneumonectomy 1,927 (24) 23.5
Unknown 89 (2) 1.1
Extent of resectionc
R0 4,023 (70) 55.8
R1 1,228 (12) 17.0
R2 144 (2) 2.0
Unknown 1,820 (23) 25.2
Positive lymph nodesc
0 2,063 (30) 28.6
1-3 3,868 (54) 53.6
4 800 (14) 11.1
Unknown 484 (9) 6.7
a Based on the weighted number of patients. b May sum to greater than 100%
because of use of more than one technique in a given patient. c Based on patients who
had a known resection.
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the PORT analysis, many patients, including patients with
stage I and II disease, were treated by pneumonectomy. In
this case, postoperative radiotherapy without CT plan can
cause unacceptable toxicity to the normal lung and heart. In
addition, expansion of the residual contralateral lung shifted
the mediastinum after the pneumonectomy. This made it very
difficult to irradiate mediastinal lymph node without CT
planning. Based on the literature, postoperative radiotherapy
is still reasonable for patients with positive margins, N2
disease, and selected N1 disease, such as extracapsular ex-
tension, or multiple N1 (hilar) involvement.
Postoperative chemotherapy has recently emerged as a
standard treatment option for most patients with resected
NSCLC, but the studies justifying its use postdate the current
PCS analysis. In 2004, the International Adjuvant Lung
Cancer Trial, a large randomized study, showed a 4.1%
improvement in 5-year survival for patients who received
adjuvant cisplatin-based chemotherapy.19 In 2005, the Na-
tional Cancer Institute of Canada trial revealed a 15% im-
provement in 5-year survival for patients who received adju-
vant vinorelbine plus cisplatin in resected stage IB or stage II
NSCLC.20 It is anticipated that adjuvant chemotherapy will
be widely accepted and will change the patterns of care for
resected NSCLC. However, the best regimen of adjuvant
chemotherapy and the optimal sequence of adjuvant chemo-
therapy with radiotherapy remain unclear. It has been shown
that adjuvant concurrent chemoradiation with cisplatin and
etoposide has no benefit compared with radiation alone in
patients with completely resected stage II and stage III-A
NSCLC.21
In conclusion, this analysis of data from the original
PCS of radiation therapy for lung cancer has elucidated how
surgery is being used in facilities throughout the United
States. Future studies will undoubtedly address whether new
trends in preoperative staging, specifically improvements in
diagnostic imaging and the use of PET scans, influence the
population of patients undergoing surgery. In addition, improve-
ments in combined modality treatments, the advent of neoadju-
vant treatment strategies, and more sophisticated CT-based
postoperative radiotherapy will likely affect future recom-
mendations of therapy for this group of operable patients.
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